News & Media
December 12, 2025 – Pfizer and TRIANA Biomedicines Named Recipients of Scrip’s 2025 Best Partnership Alliance Award for Their Collaboration on Molecular Glue Degraders
December 3, 2025 – TRIANA Biomedicines Announces Oversubscribed $120M Series B Financing to Advance its Molecular Glue Degrader Pipeline
May 7, 2025 – TRIANA Biomedicines Announces the Appointment of Caroline Germa as Chief Medical Officer and Attracts Leading Drug Discovery and Development Expert to its Scientific Advisory Board
October 15, 2024 – TRIANA Biomedicines and Pfizer Enter Into A Research Collaboration to Discover Novel Molecular Glue Degraders for Multiple Disease Areas
September 18, 2023 – TRIANA Biomedicines to Present at UBS Biotechnology Private Company Virtual Symposium
September 12, 2023 – TRIANA Biomedicines Announces the Appointments of Vito Palombella as Chief Scientific Officer and Reza Mazhari as Chief Business Officer
January 5, 2023 – TRIANA Biomedicines Named Most Promising New Company in BioSpace’s NextGen 2023 List
September 19, 2022 – TRIANA Biomedicines Announces Participation in Upcoming Investor Conference
June 23, 2022 – TRIANA Biomedicines Attracts Leading Protein Science and Clinical Oncology Experts to its Scientific Advisory Board
April 6, 2022 - TRIANA Biomedicines Launches With $110M to Unlock the Full Potential of Molecular Glues